64th ASH Annual Meeting and Exposition: 905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation

Symposia: Outcomes Research—Lymphoid Malignancies Oral and Poster Abstracts
Oral

Research, Biological therapies, Lymphoid Leukemias, ALL, adult, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, epidemiology, Clinical Research, health outcomes research, Workforce, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, pediatric, Diseases, immune mechanism, real-world evidence, Therapies, immunology, aggressive lymphoma, therapy sequence, Lymphoid Malignancies, Adverse Events, metabolism, young adult , Biological Processes, Technology and Procedures, Study Population, Human, multi-systemic interactions

291-292 (Ernest N. Morial Convention Center)

Moderators:

Doris K. Hansen, MD, H. Lee Moffitt Cancer Center & Research Institution and Carlos A. Ramos, MD, The Methodist Hospital

Disclosures:

Hansen: Survivorship: Honoraria; OncLive: Honoraria; BMS IMW Ide-Cel Academic Advisory Board: Membership on an entity's Board of Directors or advisory committees, Research Funding.

This session involves studies related to cellular immunotherapy and stem cell transplantation.

4:30 PM

997

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Macarena Oporto Espuelas¹^*, Saskia Burridge²^*, Denise Bonney, MD³^*, Kelly Watts⁴^*, Claire Roddie⁵^*, Maeve A O'Reilly⁵, Geoff Shenton⁶^*, John A Snowden⁷, Caroline Furness⁸^*, Katarzyna Aleksandra Aleksandra Jalowiec, MD⁹^*, Lorna Neill¹⁰^*, Katherine Clesham, MD PhD¹¹^*, Emma Nicholson, MD, PhD¹²^*, Anna Castleton, FRCPath¹³^*, Amit Patel, MBBS, PhD, FRCPath, MRCP¹⁴, Caroline Besley, FRCPath, PhD¹⁵^*, Robert F Wynn, MD¹⁶, Ajay Vora, MD¹⁷, David I. Marks, MBBS, PhD¹⁸, Lindsay George, PhD, FRCPath¹⁹^*, Ben Uttenthal²⁰^*, Sridhar Chaganti, MD²¹^*, Michelle Cummins²²^*, Persis J Amrolia, MD PhD²^*, Rachael E Hough, MD²³^* and Sara Ghorashian, FRCPath, PhD²⁴

¹Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, LONDON, ENG, United Kingdom
²Bone Marrow Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom
³Department of Bone Marrow Transplantation, Royal Manchester, Manchester, United Kingdom
⁴Bone Marrow Transplantation, Royal Manchester Children's Hospital, Manchester, United Kingdom
⁵University College London Hospital NHS Foundation Trust, London, United Kingdom
⁶Newcastle Hospitals NHS Foundation, Newcastle-upon-Tyne, GBR
⁷BSBMTCT, Department of Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
⁸Royal Marsden NHS Foundation Trust, royal marsden, London, United Kingdom
⁹Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
¹⁰Department of Haematology, University College London Hospitals NHS Foundation Trust, London, ENG, United Kingdom
¹¹Department of Haematology, University College London Hospitals NHS Trust, London, United Kingdom
¹²Department of Haematology/Bone marrow transplantation, The Royal Marsden NHS Foundation Trust, London, United Kingdom
¹³Haematology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
¹⁴Haematology and Transplant Unit, The Christie Hospital, Manchester, United Kingdom
¹⁵University Hospitals Bristol, Bristol, United Kingdom
¹⁶Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom
¹⁷Department of Haematology, The Children's Hospital, London, United Kingdom
¹⁸Haematology and Stem Cell Transplantation, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
¹⁹Birmingham Children's Hospital, Birmingham, GBR
²⁰Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
²¹Department of Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom
²²Department of Haematology, Bristol Children's Hospital, Bristol, GBR
²³Haematology, UCLH, London, United Kingdom
²⁴Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom

4:45 PM

998

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Veit L Buecklein, MD^1,2^*, Ariel Perez-Perez, MD³^*, Kai Rejeski, MD^2,4,5, Gloria Iacoboni, MD⁶^*, Vindi Jurinovic, PhD⁷^*, Udo Holtick, MD, PhD⁸^*, Olaf Penack, MD⁹^*, Soraya Kharboutli, MD¹⁰^*, Viktoria Blumenberg, MD^1,2,5, Josephine Ackermann²^*, Lisa Frölich²^*, Grace Johnson¹¹^*, Kedar Patel¹¹^*, Brian Arciola¹¹^*, Christian Schmidt, MD²^*, Omar Albanyan, MD¹², Philipp Gödel, MD¹³^*, Eva Hoster⁷^*, Lars Bullinger, MD⁹, Andreas Mackensen, MD¹⁴^*, Frederick L. Locke, MD¹², Michael von Bergwelt, Prof. Dr.^2,5^*, Pere Barba, MD¹⁵^*, Michael D. Jain, MD, PhD¹⁶ and Marion Subklewe, MD^1,5,17

¹Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany
²Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
³Blood & Marrow Transplant Program, Miami Cancer Institute, Miami, FL
⁴Laboratory for Translational Cancer Immunology, Gene Center, LMU, Munich, Germany
⁵German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Munich, Heidelberg, Germany
⁶Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
⁷Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany
⁸Department I of Internal Medicine, Department I of Internal Medicine,, University Hospital Cologne, Department I of Internal Medicine,, Cologne, Germany
⁹Department of Hematology, Oncology, and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
¹⁰Department of Internal Medicine 5 - Hematology/Oncology, University Hospital of Erlangen, Erlangen, Germany
¹¹USF Morsani College of Medicine, Tampa, FL
¹²Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
¹³University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
¹⁴Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany
¹⁵Department of Hematology, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain
¹⁶Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
¹⁷Department of Medicine III (Hematology/Oncology), LMU University Hospital Munich, Muenchen, Germany

5:00 PM

999

Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL

Fei Fei Liu, BSc, MBA^*, Krishnaveni Subbiah, MPH^*, Tao Gu, PhD^* and Trong Kim Le, MPH, MS^*

Bristol Myers Squibb, Princeton, NJ

5:15 PM

1000

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Ishan Roy^1,2^*, Narendranath Epperla, MD, MS³, Geoffrey Shouse, PhD, DO⁴, Jason T. Romancik, MD⁵, Tamara K. Moyo, MD, PhD⁶^*, Vaishalee P. Kenkre, MD⁷, Thomas A. Ollila, MD⁸, Lindsey A. Fitzgerald, MD⁹, Brian T. Hess, MD¹⁰, Andrew M. Evens, DO, MBA, MMSc¹¹, Joanna Zurko, MD⁷, Sayan Mullick Chowdhury, DO, PhD¹²^*, Kaitlin Annunzio, DO¹³, Robert Ferdman, MD¹⁴^*, Rahul S. Bhansali, MD¹⁵, Elyse I. Harris, MD¹⁶, McKenzie Sorrell, DO¹⁰, Jieqi Liu, MD¹⁷, Imran A. Nizamuddin, MD¹⁸, Jonathan Moreira, MD¹⁹, Shuo Ma, MD²⁰, Jane N. Winter, MD²¹, Barbara Pro, MD^22,23, Deborah M. Stephens, DO²⁴, Alexey V Danilov, MD²⁵, Nirav N. Shah, MD²⁶, Jonathon B. Cohen, MD, MS²⁷, Stefan K. Barta, MD²⁸, Pallawi Torka, MD¹⁴, Leo I. Gordon, MD²³ and Reem Karmali, MD, MSc²⁹

¹Shirley Ryan AbilityLab, Chicago, IL
²Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, IL
³The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
⁴Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
⁵Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA
⁶Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁷Carbone Cancer Center, University of Wisconsin, Madison, WI
⁸Lifespan Cancer Institute, Brown University, Providence, RI
⁹Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
¹⁰Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
¹¹Rutgers Cancer Institute of New Jersey, Warren, NJ
¹²Ohio State University Medical Center, Columbus, OH
¹³The Ohio State University, Columbus, OH
¹⁴Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹⁵Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
¹⁶Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
¹⁷Rutgers Cancer Institute of New Jersey, Hoboken, NJ
¹⁸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
¹⁹Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
²⁰Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
²¹Feinberg School of Medicine, Northwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
²²Department of Hematology and Oncology, Columbia University Medical Center, New York, NY
²³Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
²⁴Huntsman Cancer Institute, Salt Lake City, UT
²⁵City of Hope Comprehensive Cancer Center, Duarte, CA
²⁶Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
²⁷Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
²⁸Abramson Cancer Center, Lymphoma Program, University of Pennsylvania, Philadelphia, PA
²⁹Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL

5:30 PM

1001

Why Are Patients Not Getting a Graft? an Intent-to-Transplant Analysis in the Times of Universal Coverage and Haploidentical Donors

Yadith Karina Lopez-Garcia, MD¹^*, Christianne Bourlon De Los Rios, MD, MSc², Perla Rocio Colunga-Pedraza, MD¹, Cesar Omar Vargas-Serafin, MD²^*, Alberto Vazquez Mellado de Larracoechea³^*, Lourdes Gil-Flores¹, Nidia Moncada Saucedo¹^*, Moisés Manuel Gallardo-Pérez, MD⁴^*, David Gomez-Almaguer, MD⁵, Guillermo José Ruiz-Argüelles, MD, FRCP (Glasg), MACP, DSc(hc), FRCP⁶ and Andres Gomez-De Leon, MD¹

¹Servicio de Hematología, Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. José Eleuterio Gonzalez", Monterrey, Mexico
²Department of Hematology and Oncology, Instituto Nacional De Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico
³Clínica Hematológica, Queretaro, Mexico
⁴Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico
⁵Servicio de Hematología, Universidad Autónoma de Nuevo León. Facultad de Medicina y Hospital Universitario “Dr. José Eleuterio González”, Monterrey, NL, Mexico
⁶Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, PU, Mexico

5:45 PM

1002

Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US

Dai Chihara, MD¹, Laura Liao²^*, Joseph Tkacz, MS³^*, Benjamin Lewing, PhD³^*, Anjali Franco, MS³^*, Karl M. Kilgore, PhD³^*, Loretta J. Nastoupil, MD¹ and Lei Chen, MD, PhD²^*

¹MD Anderson Cancer Center, Houston, TX
²ADC Therapeutics America, Inc., New Providence, NJ
³Inovalon, Bowie, MD

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

905.O5.6 905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation